November 25, 2022
Japan’s Ministry of Health, Labor and Welfare (MHLW) on November 24 approved label expansions for four cancer medicines including Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan). Enhertu saw certain restrictions lifted for its breast cancer indication. It was...read more